Exploring contemporary breakthroughs in utilizing vesicular nanocarriers for breast cancer therapy.

Autor:	Kumari NU; Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research, Hyderabad, Telangana, 500037, India., Pardhi E; Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research, Hyderabad, Telangana, 500037, India., Chary PS; Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research, Hyderabad, Telangana, 500037, India., Mehra NK; Department of Pharmaceutics, National Institute of Pharmaceutical Education & Research, Hyderabad, Telangana, 500037, India.
Jazyk:	angličtina
Zdroj:	Therapeutic delivery [Ther Deliv] 2024 Apr; Vol. 15 (4), pp. 279-303. Date of Electronic Publication: 2024 Feb 20.
DOI:	10.4155/tde-2023-0092
Abstrakt:	Breast cancer (BC) is a heterogeneous disease with various morphological features, clinicopathological conditions and responses to different therapeutic options, which is responsible for high mortality and morbidity in women. The heterogeneity of BC necessitates new strategies for diagnosis and treatment, which is possible only by cautious harmonization of the advanced nanomaterials. Recent developments in vesicular nanocarrier therapy indicate a paradigm shift in breast cancer treatment by providing an integrated approach to address current issues. This review provides a detailed classification of various nanovesicles in the treatment of BC with a special emphasis on recent advances, challenges in translating nanomaterials and future potentials.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu